Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, ...

Sanofi (SNYNF, SNY) reported fourth quarter net income from continuing operations of 880 million euros compared to a loss of 119 ...

PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Thursday reported fourth-quarter earnings of $728.6 million. The company said it had net income of 29 cents per share. Earnings, adjusted for non-recurring ...

Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...

Welcome to the Q4 and Full Year 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual forward ...

We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with ...

Sanofi SNY reported fourth-quarter 2024 adjusted earnings of 70 cents per American depositary share, which missed the Zacks Consensus Estimate of 71 cents per share. Earnings of €1.31 per share ...